MA46219B1 - Composés de co-agonistes du glucagon et du glp-1 - Google Patents

Composés de co-agonistes du glucagon et du glp-1

Info

Publication number
MA46219B1
MA46219B1 MA46219A MA46219A MA46219B1 MA 46219 B1 MA46219 B1 MA 46219B1 MA 46219 A MA46219 A MA 46219A MA 46219 A MA46219 A MA 46219A MA 46219 B1 MA46219 B1 MA 46219B1
Authority
MA
Morocco
Prior art keywords
glp
glucagon
compounds
agonists
alcoholic
Prior art date
Application number
MA46219A
Other languages
English (en)
Other versions
MA46219A (fr
Inventor
Yanyun Chen
Adam Robert MEZO
Hongchang Qu
Francisco Alcides VALENZUELA
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MA46219A publication Critical patent/MA46219A/fr
Publication of MA46219B1 publication Critical patent/MA46219B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La présente invention concerne des composés de co-agonistes du glucagon et du glp-1 qui sont utiles dans le traitement du diabète de type 2, de l'obésité, de la stéatose hépatique non alcoolique (nafld) et/ou de la stéatohépatite non alcoolique (nash) p-20637
MA46219A 2015-06-22 2016-06-16 Composés de co-agonistes du glucagon et du glp-1 MA46219B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562182847P 2015-06-22 2015-06-22
PCT/US2016/037818 WO2016209707A1 (fr) 2015-06-22 2016-06-16 Composés de co-agonistes du glucagon et du glp-1

Publications (2)

Publication Number Publication Date
MA46219A MA46219A (fr) 2018-04-25
MA46219B1 true MA46219B1 (fr) 2020-12-31

Family

ID=56289604

Family Applications (2)

Application Number Title Priority Date Filing Date
MA054407A MA54407A (fr) 2015-06-22 2016-06-16 Composés de co-agonistes du glucagon et du glp-1
MA46219A MA46219B1 (fr) 2015-06-22 2016-06-16 Composés de co-agonistes du glucagon et du glp-1

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MA054407A MA54407A (fr) 2015-06-22 2016-06-16 Composés de co-agonistes du glucagon et du glp-1

Country Status (40)

Country Link
US (1) US9938335B2 (fr)
EP (2) EP3310371B1 (fr)
JP (4) JP6585197B2 (fr)
KR (2) KR102544419B1 (fr)
CN (2) CN107735100B (fr)
AR (1) AR104932A1 (fr)
AU (1) AU2016283984B2 (fr)
BR (1) BR112017024684A2 (fr)
CA (1) CA2987489A1 (fr)
CL (1) CL2017003185A1 (fr)
CO (1) CO2018000078A2 (fr)
CR (1) CR20170534A (fr)
CY (1) CY1123591T1 (fr)
DK (1) DK3310371T3 (fr)
DO (1) DOP2017000303A (fr)
EA (1) EA038720B1 (fr)
EC (1) ECSP17084280A (fr)
ES (1) ES2833458T3 (fr)
HK (1) HK1245669A1 (fr)
HR (1) HRP20201881T1 (fr)
HU (1) HUE052684T2 (fr)
IL (4) IL285231B (fr)
JO (1) JO3686B1 (fr)
LT (1) LT3310371T (fr)
MA (2) MA54407A (fr)
MD (1) MD3310371T2 (fr)
MX (1) MX2017016198A (fr)
MY (1) MY190210A (fr)
NZ (1) NZ737050A (fr)
PE (2) PE20231639A1 (fr)
PH (1) PH12017502359A1 (fr)
PL (1) PL3310371T3 (fr)
PT (1) PT3310371T (fr)
RS (1) RS61107B1 (fr)
SI (1) SI3310371T1 (fr)
SV (1) SV2017005594A (fr)
TN (1) TN2017000531A1 (fr)
TW (3) TWI700291B (fr)
UA (1) UA122692C2 (fr)
WO (1) WO2016209707A1 (fr)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI700291B (zh) * 2015-06-22 2020-08-01 美國禮來大藥廠 升糖素及glp-1共激動劑化合物
JOP20170153A1 (ar) * 2016-07-15 2019-01-30 Lilly Co Eli نظائر urocortin-2 جديدة معدلة بحمض دهني لعلاج داء السكري وأمراض الكلى المزمنة
CN108299553B (zh) * 2017-01-13 2021-07-16 博瑞生物医药（苏州）股份有限公司 胃泌酸调节素修饰物
AU2018336482B2 (en) * 2017-09-19 2021-08-12 Immunwork Inc. Pharmaceutical constructs with enhanced binding affinity with albumin
EP3708577A4 (fr) * 2017-11-06 2021-09-01 Shenzhen Turier Biotech Co., Ltd. Traitement de la cirrhose biliaire à base de peptide agoniste double cible de glp-1r/gcgr d'oxyntomoduline
TWI809515B (zh) * 2017-12-21 2023-07-21 美商美國禮來大藥廠 腸促胰島素(incretin)類似物及其用途
TWI810937B (zh) * 2017-12-21 2023-08-01 美商美國禮來大藥廠 腸促胰島素(incretin)類似物及其用途
WO2019140025A1 (fr) 2018-01-12 2019-07-18 Eli Lilly And Company Polythérapie
CN111171134B (zh) * 2018-11-12 2023-08-15 天津药物研究院有限公司 胰高血糖素衍生肽及其用途
CN111171135B (zh) * 2018-11-12 2023-04-07 天津药物研究院有限公司 具有双重受体激动作用的胰高血糖素衍生肽及其用途
CN111423506B (zh) * 2019-11-08 2023-06-27 成都奥达生物科技有限公司 一种glp-1化合物
US20230265151A1 (en) * 2020-01-23 2023-08-24 Eli Lilly And Company Gip/glp1 co-agonist compounds
CN113336840B (zh) * 2020-03-02 2022-09-23 武汉帕肽生物医药有限责任公司 订书肽、其制备方法和用途
JP2023516806A (ja) * 2020-03-11 2023-04-20 エニジェン カンパニー リミテッド 新規化合物を含む抗糖尿病及び抗肥満用組成物
CN113493504B (zh) * 2020-03-18 2024-02-27 深圳纳福生物医药有限公司 GIP-Exendin-4嵌合肽的分子改构及其二聚体在治疗糖尿病中的应用
US20230295077A1 (en) * 2020-04-10 2023-09-21 Fresenius Kabi Oncology Limited An improved process for the preparation of semaglutide side chain
WO2021221482A1 (fr) 2020-04-29 2021-11-04 주식회사 원진바이오테크놀로지 Nouveau conjugué de protéine et son utilisation pour la prévention ou le traitement de la stéatohépatite non alcoolique, de l'obésité et du diabète
AR122579A1 (es) * 2020-06-12 2022-09-21 Lilly Co Eli Proceso para preparar un agonista dual glp-1 / glucagón
US20230310631A1 (en) * 2020-07-15 2023-10-05 Hanmi Pharm. Co., Ltd. Therapeutic use of glucagon derivative or conjugate thereof for liver disease
TW202239427A (zh) 2020-12-22 2022-10-16 美商美國禮來大藥廠 治療肽調配物
CN112898405B (zh) * 2021-01-22 2023-02-28 深圳市图微安创科技开发有限公司 多肽化合物及其在预防或治疗糖尿病或糖尿病并发症中的应用
CN116410297A (zh) * 2021-07-19 2023-07-11 内蒙古博睿精创科技有限公司 长效glp-1多肽类似物及其制备方法和应用
WO2023016346A1 (fr) * 2021-08-10 2023-02-16 南京明德新药研发有限公司 Composé polypeptidique contenant un pont lactame
KR20230037391A (ko) * 2021-09-09 2023-03-16 애니젠 주식회사 신규한 화합물을 포함하는 염증성 장질환 예방 또는 치료용 조성물
WO2023088143A1 (fr) * 2021-11-19 2023-05-25 南京明德新药研发有限公司 Polypeptides contenant des agrafes et leur application
TW202404996A (zh) 2022-04-04 2024-02-01 美商美國禮來大藥廠 製備glp-1/升糖素雙重促效劑之方法
CN116970064A (zh) * 2022-04-29 2023-10-31 苏州星洲生物科技有限公司 Glp-1/gcg受体共激动剂、包含其的药物组合物及其用途
WO2023231730A2 (fr) * 2022-06-01 2023-12-07 信达生物制药(苏州)有限公司 Méthode de traitement utilisant du mazdutide
WO2023235724A1 (fr) 2022-06-01 2023-12-07 Eli Lilly And Company Procédés d'utilisation d'un co-agoniste gcg/glp1 pour une thérapie
CN115490760B (zh) * 2022-07-04 2023-04-14 北京惠之衡生物科技有限公司 一种glp-1受体和gcg受体共激动多肽衍生物
CN117586373A (zh) * 2022-08-10 2024-02-23 成都奥达生物科技有限公司 一种长效双激动剂化合物
WO2024050289A1 (fr) 2022-08-29 2024-03-07 Eli Lilly And Company Compositions pour administration orale
WO2024077149A2 (fr) * 2022-10-05 2024-04-11 Eli Lilly And Company Peptides pour la synthèse d'incrétine

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2778047A1 (fr) * 1998-12-07 2000-06-15 Ipsen Pharma S.A.S Analogues du glp-1
CA2852177A1 (fr) * 2008-06-17 2009-12-23 Indiana University Research And Technology Corporation Co-agonistes du recepteur glucagon/glp-1
EA019203B9 (ru) * 2008-06-17 2014-03-31 Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн Коагонисты глюкагонового рецептора/glp-1-рецептора
EP2512503A4 (fr) 2009-12-18 2013-08-21 Univ Indiana Res & Tech Corp Co-agonistes du récepteur du glucagon/glp-i
JO2976B1 (en) 2009-12-22 2016-03-15 ايلي ليلي اند كومباني Axentomodulin polypeptide
KR20120123443A (ko) * 2010-01-27 2012-11-08 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 대사 장애 및 비만 치료용 글루카곤 길항제-ｇｉｐ 항진제 콘쥬게이트
BR112013032717A2 (pt) 2011-06-22 2017-01-24 Univ Indiana Res & Tech Corp coagonistas do receptor de glucagon/glp-1
WO2013004983A1 (fr) * 2011-07-04 2013-01-10 Imperial Innovations Limited Nouveaux composés et leurs effets sur le comportement alimentaire
CN103957927B (zh) * 2011-11-17 2016-11-09 印第安纳大学研究及科技有限公司 呈现糖皮质激素受体活性的胰高血糖素超家族肽
US9546205B2 (en) * 2012-09-17 2017-01-17 Imperial Innovations Limited Peptide analogues of glucagon and GLP1
TWI608013B (zh) 2012-09-17 2017-12-11 西蘭製藥公司 升糖素類似物
UA116217C2 (uk) * 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
EP2986314A4 (fr) * 2013-03-15 2016-04-13 Univ Indiana Res & Tech Corp Promédicaments et une action prolongée
TWI700291B (zh) * 2015-06-22 2020-08-01 美國禮來大藥廠 升糖素及glp-1共激動劑化合物

Also Published As

Publication number Publication date
JP6585197B2 (ja) 2019-10-02
NZ737050A (en) 2019-08-30
AU2016283984A1 (en) 2017-11-23
CN113956348A (zh) 2022-01-21
SI3310371T1 (sl) 2020-11-30
JP2018521043A (ja) 2018-08-02
TW201716431A (zh) 2017-05-16
LT3310371T (lt) 2020-12-28
JP6985345B2 (ja) 2021-12-22
PE20180523A1 (es) 2018-03-14
TW201906857A (zh) 2019-02-16
US20160368960A1 (en) 2016-12-22
CN107735100A (zh) 2018-02-23
ECSP17084280A (es) 2018-02-28
BR112017024684A2 (pt) 2018-09-11
KR20180004276A (ko) 2018-01-10
PL3310371T3 (pl) 2021-03-08
JP2024016243A (ja) 2024-02-06
KR102034607B1 (ko) 2019-10-22
CA2987489A1 (fr) 2016-12-29
IL294099A (en) 2022-08-01
CR20170534A (es) 2018-02-27
EP3310371A1 (fr) 2018-04-25
ES2833458T3 (es) 2021-06-15
HK1245669A1 (zh) 2018-08-31
UA122692C2 (uk) 2020-12-28
MY190210A (en) 2022-04-05
HUE052684T2 (hu) 2021-05-28
CL2017003185A1 (es) 2018-06-01
CN107735100B (zh) 2021-11-05
MA46219A (fr) 2018-04-25
TWI669309B (zh) 2019-08-21
HRP20201881T1 (hr) 2021-01-22
DOP2017000303A (es) 2018-01-15
KR20190119676A (ko) 2019-10-22
EA201792562A1 (ru) 2018-05-31
DK3310371T3 (da) 2020-10-12
TWI783244B (zh) 2022-11-11
IL294099B1 (en) 2023-11-01
WO2016209707A1 (fr) 2016-12-29
KR102544419B1 (ko) 2023-06-19
CO2018000078A2 (es) 2018-03-28
IL294099B2 (en) 2024-03-01
TN2017000531A1 (en) 2019-04-12
TWI700291B (zh) 2020-08-01
JP2022031787A (ja) 2022-02-22
JO3686B1 (ar) 2020-08-27
EA038720B1 (ru) 2021-10-11
MA54407A (fr) 2021-10-13
AU2016283984B2 (en) 2018-11-29
PH12017502359B1 (en) 2018-06-25
PT3310371T (pt) 2020-12-15
SV2017005594A (es) 2018-04-24
PH12017502359A1 (en) 2018-06-25
CY1123591T1 (el) 2022-03-24
IL255723A (en) 2018-01-31
IL255723B (en) 2021-08-31
AR104932A1 (es) 2017-08-23
US9938335B2 (en) 2018-04-10
IL285231B (en) 2022-08-01
MD3310371T2 (ro) 2020-12-31
EP3785724A1 (fr) 2021-03-03
MX2017016198A (es) 2018-03-01
PE20231639A1 (es) 2023-10-16
IL307657A (en) 2023-12-01
JP2020007338A (ja) 2020-01-16
RS61107B1 (sr) 2020-12-31
JP7386218B2 (ja) 2023-11-24
TW202118775A (zh) 2021-05-16
IL285231A (en) 2021-09-30
EP3310371B1 (fr) 2020-09-30

Similar Documents

Publication Publication Date Title
MA46219B1 (fr) Composés de co-agonistes du glucagon et du glp-1
MA41013A (fr) Compositions comprenant des souches bactériennes
EA201890145A1 (ru) Антитела к фактору xi и способы их применения
EA201290964A1 (ru) Пептидные конъюгаты агонистов рецептора glp-1 и их применение
UY31114A1 (es) Anticuerpos humanizados contra el globulómero ab(20-42) y sus usos
PH12017501522B1 (en) Antibodies to tau and uses thereof
EA201101117A1 (ru) Ингибиторы дпп-4 для лечения диабета у детей
UA118332C2 (uk) Білок, що зв'язує антиген cd27l
EA201501032A1 (ru) Фармацевтическая композиция, способы лечения и ее применения
EA201101524A1 (ru) Способ и композиция для лечения состояния, связанного с хемосенсорным рецептором
EA200800355A1 (ru) Нейтрализующие антитела человека против b7rp1
EA201690159A1 (ru) Способы и композиции для лечения рака
MX2022015250A (es) Un anticuerpo anti-il-23a para usarse en el tratamiento de la enfermedad de crohn.
EA201690964A1 (ru) Композиции и способы для уменьшения серьезных неблагоприятных сердечно-сосудистых явлений
SG178596A1 (en) Methods of treatment using anti-oxidized ldl antibodies
MX2019014365A (es) Tratamiento topico de la enfermedad intestinal inflamatoria usando anticuerpos y fragmentos de los mismos.
MX2019002579A (es) Composiciones y metodos de uso de depuradores de gamma-cetoaldehido para tratar, evitar o mejorar la enfermedad del higado graso no alcoholico (nafld), nash, ald o condiciones relacionadas al higado.
MA39228A1 (fr) Compositions à utiliser pour le traitement d'états allergiques
MX2017006747A (es) Amidas de acidos grasos para la prevencion y/o tratamiento de la esteatohepatitis.
NZ702645A (en) A method of improving liver function
Guglielmi Liver toxicity: case report
MA40908B1 (fr) Anticorps anti-il-6 améliorés